Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Overview

Journal Hepat Oncol

Date 2018 Sep 8

PMID 30191057

Citations 8

Authors

Stephanie Klein

Jean-Francois Dufour

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease is becoming more common globally. The incidence of HCC due to nonalcoholic steatohepatitis in comparison to other etiologies is increasing. This is due to the pandemic of obesity and diabetes mellitus, two important risk factors for HCC. HCC arising in this context occurs in about 40% of the cases in a liver which is not yet cirrhotic. This has implications regarding the population which should be enrolled in an HCC surveillance program and regarding the treatment options. Surgery is more frequently contemplated in patients with HCC and no cirrhosis. However, patients with nonalcoholic steatohepatitis-induced HCC have frequent co-morbidities which have to be taken into account when developing a management strategy. Interestingly, these patients are frequently on medications which have been suggested to decrease the risk to develop HCC.

Citing Articles

p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway.

Fondevila M, Novoa E, Gonzalez-Rellan M, Fernandez U, Heras V, Porteiro B Cell Rep Med. 2024; 5(2):101401.

PMID: 38340725 PMC: 10897550. DOI: 10.1016/j.xcrm.2024.101401.

Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise.

Singh A, Singh S, Kumar R, Kumar S, Senapati S, Pandey A World J Hepatol. 2023; 15(1):1-18.

PMID: 36744169 PMC: 9896505. DOI: 10.4254/wjh.v15.i1.1.

Liver-on-a-chip: Considerations, advances, and beyond.

Yang Z, Liu X, Cribbin E, Kim A, Li J, Yong K Biomicrofluidics. 2022; 16(6):061502.

PMID: 36389273 PMC: 9646254. DOI: 10.1063/5.0106855.

MiR-22 Deficiency Fosters Hepatocellular Carcinoma Development in Fatty Liver.

Gjorgjieva M, Ay A, Correia de Sousa M, Delangre E, Dolicka D, Sobolewski C Cells. 2022; 11(18).

PMID: 36139435 PMC: 9496902. DOI: 10.3390/cells11182860.

Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma.

Feng S, Meng X, Li Z, Chang T, Wu X, Zhou J J Med Chem. 2021; 64(21):15639-15650.

PMID: 34590489 PMC: 9007039. DOI: 10.1021/acs.jmedchem.1c00697.

References

Kuriyama S, Tsubono Y, Hozawa A, Shimazu T, Suzuki Y, Koizumi Y . Obesity and risk of cancer in Japan. Int J Cancer. 2004; 113(1):148-57. DOI: 10.1002/ijc.20529. View

Tsan Y, Lee C, Wang J, Chen P . Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012; 30(6):623-30. DOI: 10.1200/JCO.2011.36.0917. View

Yang G, Wang Y, Feng J, Liu Y, Wang T, Zhao M . Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling. Biochem Biophys Res Commun. 2017; 486(3):827-832. DOI: 10.1016/j.bbrc.2017.03.139. View

Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V . Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2008; 49(3):851-9. DOI: 10.1002/hep.22734. View

Flemming J, Kim W, Brosgart C, Terrault N . Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2016; 65(3):804-812. PMC: 5333888. DOI: 10.1002/hep.28923. View

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

Calle E, Rodriguez C, Walker-Thurmond K, Thun M . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17):1625-38. DOI: 10.1056/NEJMoa021423. View

Moller H, Mellemgaard A, Lindvig K, Olsen J . Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994; 30A(3):344-50. DOI: 10.1016/0959-8049(94)90254-2. View

Lai S, Chen P, Liao K, Muo C, Lin C, Sung F . Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2011; 107(1):46-52. DOI: 10.1038/ajg.2011.384. View

10.

Goldberg D, Ditah I, Saeian K, Lalehzari M, Aronsohn A, Gorospe E . Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017; 152(5):1090-1099.e1. PMC: 5367965. DOI: 10.1053/j.gastro.2017.01.003. View

11.

Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S . Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511. PMC: 4587544. DOI: 10.1038/ng.3252. View

12.

Adami H, Chow W, Nyren O, Berne C, Linet M, Ekbom A . Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996; 88(20):1472-7. DOI: 10.1093/jnci/88.20.1472. View

13.

Welzel T, Graubard B, Zeuzem S, El-Serag H, Davila J, McGlynn K . Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54(2):463-71. PMC: 4141525. DOI: 10.1002/hep.24397. View

14.

Iannacone M, Sitia G, Narvaiza I, Ruggeri Z, Guidotti L . Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin Vaccine Immunol. 2007; 14(11):1532-5. PMC: 2168169. DOI: 10.1128/CVI.00298-07. View

15.

Zoller H, Tilg H . Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism. 2016; 65(8):1151-60. DOI: 10.1016/j.metabol.2016.01.010. View

16.

Wong R, Aguilar M, Cheung R, Perumpail R, Harrison S, Younossi Z . Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2014; 148(3):547-55. DOI: 10.1053/j.gastro.2014.11.039. View

17.

Balasus D, Way M, Fusilli C, Mazza T, Morgan M, Cervello M . The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget. 2016; 7(52):86791-86802. PMC: 5349954. DOI: 10.18632/oncotarget.13558. View

18.

Seo Y, Kim Y, Kim M, Suh K, Kim S, Han C . Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study. Medicine (Baltimore). 2016; 95(17):e3527. PMC: 4998724. DOI: 10.1097/MD.0000000000003527. View

19.

Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F . Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A. 2012; 109(32):E2165-72. PMC: 3420192. DOI: 10.1073/pnas.1209182109. View

20.

Desbois A, Cacoub P . Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol. 2017; 23(9):1697-1711. PMC: 5340821. DOI: 10.3748/wjg.v23.i9.1697. View